ML-SA1, a TRPML1 agonist, induces gastric secretion and gastrointestinal tract inflammation in vivo
Background: The effect of ML-SA1, a potent and specific TRPML1 channel agonist, on gastric secretion and subsequent impact to the gastrointestinal (GI) tract of mice was investigated.
Methods: Twenty mice were divided into two groups, and respectively received either ML-SA1 or DMSO alone (as negative control), and then the intestinal propulsion rate were monitored. The stomach and intestinal tissues were sectioned for periodic acid Schiff (PAS), histopathological or immunohistochemical (IHC) analysis. TRPML1 expression level in AGS cells was assayed by western blot, and calcium imaging was performed in AGS cells after the GCaMP5G transfection.
Results: Application of 150 μg/Kg ML-SA1 could result in significant decrease in intestinal propulsion rate and structural changes of the parietal cells in stomach and goblet cells in intestine of mice. Moreover, it induced inflammation to the duodenum section of intestine in mice. IHC staining also revealed that ML-SA1 could up-regulate TRPML1 expression in both the parietal cells of stomach pits and in the columnar epithelial cells of duodenum villi. Further study in AGS cells, a type of stomach cell line, demonstrated that ML-SA1 could enhance the expression of TRPML1 and induce the protrusion of micro-vesicles.
Conclusions: All together, our results suggested that ML-SA1 was capable of activating TRPML1 in stomach cells and increasing gastric juice secretion. This provided a convincing attempt of applying ML-SA1 in animals and pointed out a new possible research direction that TRPML1 channel could be a potential new therapeutic target on hypochlorhydria or even in the field of gastrointestinal cancer research.
Fatima R, Aziz M. Achlorhydria. StatPearls. Treasure Island (FL)2019.
Belei OA, Heredea ER, Boeriu E, Marcovici TM, Cerbu S, Marginean O, et al. Verner-Morrison syndrome. Literature review. Rom J Morphol Embryol. 2017;58(2):371-6.
Giusti F, Marini F, Brandi ML. Multiple Endocrine Neoplasia Type 1. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al., editors. GeneReviews((R)). Seattle (WA)1993.
Lechner K, Fodinger M, Grisold W, Puspok A, Sillaber C. [Vitamin B12 deficiency. New data on an old theme]. Wien Klin Wochenschr. 2005;117(17):579-91.
Sahoo N, Gu M, Zhang X, Raval N, Yang J, Bekier M, et al. Gastric acid secretion from parietal cells is mediated by a Ca(2+) efflux channel in the tubulovesicle. Dev Cell. 2017;41(3):262-73 e6.
Di Paola S, Scotto-Rosato A, Medina DL. TRPML1: The Ca((2+))retaker of the lysosome. Cell Calcium. 2018;69:112-21.
LaPlante JM, Falardeau J, Sun M, Kanazirska M, Brown EM, Slaugenhaupt SA, et al. Identification and characterization of the single channel function of human mucolipin-1 implicated in mucolipidosis type IV, a disorder affecting the lysosomal pathway. FEBS Lett. 2002;532(1-2):183-7.
Dong XP, Cheng X, Mills E, Delling M, Wang F, Kurz T, et al. The type IV mucolipidosis-associated protein TRPML1 is an endolysosomal iron release channel. Nature. 2008;455(7215):992-6.
Xu H, Delling M, Li L, Dong X, Clapham DE. Activating mutation in a mucolipin transient receptor potential channel leads to melanocyte loss in varitint-waddler mice. Proc Natl Acad Sci USA. 2007;104(46):18321-6.
Medina DL, Fraldi A, Bouche V, Annunziata F, Mansueto G, Spampanato C, et al. Transcriptional activation of lysosomal exocytosis promotes cellular clearance. Dev Cell. 2011;21(3):421-30.
Li X, Rydzewski N, Hider A, Zhang X, Yang J, Wang W, et al. A molecular mechanism to regulate lysosome motility for lysosome positioning and tubulation. Nat Cell Biol. 2016;18(4):404-17.
Clark R, Griffiths GM. Lytic granules, secretory lysosomes and disease. Curr Opin Immunol. 2003;15(5):516-21.
Shen D, Wang X, Li X, Zhang X, Yao Z, Dibble S, et al. Lipid storage disorders block lysosomal trafficking by inhibiting a TRP channel and lysosomal calcium release. Nat Commun. 2012;3:731.
Wu LG, Hamid E, Shin W, Chiang HC. Exocytosis and endocytosis: modes, functions, and coupling mechanisms. Annu Rev Physiol. 2014;76:301-31.
Gomez NM, Lu W, Lim JC, Kiselyov K, Campagno KE, Grishchuk Y, et al. Robust lysosomal calcium signaling through channel TRPML1 is impaired by lysosomal lipid accumulation. FASEB J. 2018;32(2):782-94.
Grimm C, Bartel K, Vollmar AM, Biel M. Endolysosomal cation channels and cancer-a link with great potential. Pharmaceuticals. 2018;11(1).
Jung J, Cho KJ, Naji AK, Clemons KN, Wong CO, Villanueva M, et al. HRAS-driven cancer cells are vulnerable to TRPML1 inhibition. EMBO Rep. 2019;20(4).
Xu M, Almasi S, Yang Y, Yan C, Sterea AM, Rizvi Syeda AK, et al. The lysosomal TRPML1 channel regulates triple negative breast cancer development by promoting mTORC1 and purinergic signaling pathways. Cell Calcium. 2019;79:80-8.
Capurro MI, Greenfield LK, Prashar A, Xia S, Abdullah M, Wong H, et al. VacA generates a protective intracellular reservoir for Helicobacter pylori that is eliminated by activation of the lysosomal calcium channel TRPML1. Nat Microbiol. 2019;4(8):1411-23.
Copyright (c) 2019 Dan Gong, Jing Hai, Jun Ma, Chen-Xi Wang, Xin-Dan Zhang, Ya-Nan Xiang, Tao Tan, Ya-Nan Liu, Wei Zhang
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain full copyright to their individual works.
In accordance with the Budapest Open Access Initiative, articles published in STEMedicine are freely available "on the public internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself. The only constraint on reproduction and distribution, and the only role for copyright in this domain, should be to give authors control over the integrity of their work and the right to be properly acknowledged and cited."
Except where otherwise noted, all content on this website is licensed under a Creative Commons Attribution 4.0 License. This license allows for commercial and non-commercial redistribution as well as modifications of the work as long as attribution is given to the authors and STEMedicine as the original publication source, and a link to the article on the STEMedicine website is provided.